Trimerbody

LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. 
 
Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.
 
By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate. 
 
Trimerbody® is a registered trademark and is covered by international patents.

Latest News

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...

Leadartis closes the investment round in 14 days with an overfunding of 25%
28-09-2020

We are pleased to inform you that the investment round has been successfully closed, raising a...

Fund Raising Update: Round completed
21-09-2020

In only ten days Leadartis has completed 100% of its fund-raising needs.

We thank you all...